Influvac^® (Influenza Vaccine/Surface Antigen/Inactivated)¹

Influvac^® Tetra is an inactivated (surface antigen), quadrivalent influenza vaccine indicated for the prophylaxis of influenza, especially in those who run an increased risk of associated complications.

The use of Influvac^® sub-unit Tetra should be based on official recommendations.

Influvac^® Tetra is indicated in adults and children from 6 months of age.

Influvac^® Tetra complies with the World Health Organisation (WHO) recommendation (northern hemisphere) and EU recommendation for the 2022/2023 season.

Influvac® Tetra provides active immunisation against 4 influenza virus strains. This vaccine complies with the World Health Organisation (WHO) recommendation (northern hemisphere) and EU recommendation for the 2022/2023 season.¹

• - A/Victoria/2570/2019 (H1N1)pdm09-like strain
  (A/Victoria/2570/2019, IVR-215)
  - A/Darwin/9/2021 (H3N2)-like strain
  (A/Darwin/9/2021, SAN-010)
  - B/Austria/1359417/2021-like strain
  (B/Austria/1359417/2021, BVR-26)
  - B/Phuket/3073/2013-like strain
  (B/Phuket/3073/2013, wild type)

Influvac^® Tetra can be used in all stages of pregnancy and during breastfeeding.¹

Influvac^® Tetra is available in pre-filled, single-dose syringe (Single packs: syringes with needles. Packs of ten: Syringes can be ordered with/without needle).¹

For many years, flu vaccines were designed to protect against three different flu viruses: an influenza A(H1N1) virus, an influenza A(H3N2) virus and one influenza B virus, even though there are two different lineages of B viruses that circulate during most seasons. Adding a B virus from the second lineage was done to give broader protection against circulating flu viruses.²

A quadrivalent influenza (flu) vaccine is designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses.²